# Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

> **NCT02267512** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 280 (actual)

## Conditions studied

- De Novo Kidney Transplant Patients

## Interventions

- **DRUG:** ATG-F

## Key facts

- **NCT ID:** NCT02267512
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-31
- **Primary completion:** 2015-12-31
- **Final completion:** 2015-12-31
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2024-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267512, "Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02267512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*